Literature DB >> 21088970

[§ 116b SGB V (social insurance code, book five) for rheumatology patients. An empirical assessment on the basis of administrative data].

T Rath1, E Bokern, E Sefo-Bukow, G Büscher, M Lüngen, A Rubbert-Roth.   

Abstract

BACKGROUND: The choice between outpatient and inpatient care is currently undergoing major changes within the German health care system with the amendment of § 116b SGB V. This study investigates what proportion of hitherto inpatient rheumatologic care could potentially be given on an outpatient basis.
METHODS: The analysis is based on administrative inpatient data from 2004 to 2008 covering approximately 23.6 million private health insurance insurants. The selection of patients with rheumatological diseases was based on diagnosis according to ICD-10 of § 116b SGB V.
RESULTS: From 2004 to 2008 the number of all rheumatologic cases increased by 13.9%, while the average length of hospital stay decreased from 9.46 days to 8.08 days and the number of attending hospitals declined by 3.1%. The number of rheumatologic cases with a short inpatient stay (≤2 days) increased by 32.3%. We define the ambulatory potential as the proportion of patients with a short length of stay to the total of inpatient rheumatologic cases; this increased from 25.7% to 29.9%. DISCUSSION: Not all patients with a short inpatient stay can be transferred problem-free to ambulatory care. No channeling of patients to specialized centres has taken place thus far in Germany. Quality of care at the hospitals studied has not been considered. Further data are needed to link administrative data with quality care data.

Entities:  

Mesh:

Year:  2011        PMID: 21088970     DOI: 10.1007/s00393-010-0703-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  8 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

Review 2.  [Analysis of mortality and convergence tendencies in inpatient care of stroke and myocardial infarction].

Authors:  T Rath; G Büscher; D Schwartze; A Drabik; E Bokern; M Lüngen
Journal:  Herz       Date:  2010-08-11       Impact factor: 1.443

3.  [Increasingly appropriate depiction of rheumatology for G-DRG reimbursement 2006].

Authors:  H J Lakomek; W Fiori; K Buscham; J Hülsemann; N Köneke; W Liman; E Märker-Hermann; N Roeder
Journal:  Z Rheumatol       Date:  2006-02       Impact factor: 1.372

4.  [Convergence tendencies in inpatient oncological care after implementation of diagnosis-related groups in Germany].

Authors:  M Lüngen; T Rath; D Schwartze; G Büscher; E Bokern
Journal:  Gesundheitswesen       Date:  2009-05-19

5.  [Structural quality of acute internal medicine rheumatology clinics--Project Group of the Association of Rheumatologic Acute Clinics].

Authors:  H J Lakomek; G Neeck; B Lang; J Jung
Journal:  Z Rheumatol       Date:  2002-08       Impact factor: 1.372

Review 6.  [Value of inpatient care in rheumatoid arthritis-an evidence based report].

Authors:  M Schneider; M Lelgemann; C Baerwald; J Braun; M Hammer; P Kern; A Krause; R Alten; U Faubel; M Hammer; J Lakomek; W Liman; Th Pauly; A Schnabel
Journal:  Z Rheumatol       Date:  2004-10       Impact factor: 1.372

Review 7.  [Structures of acute rheumatic care].

Authors:  M Stier-Jarmer; W Liman; G Stucki; J Braun
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

8.  [Oncologic surgical procedures in ambulatory and brief inpatient surgery].

Authors:  J Fahlke; F Eder; M Pross; H Lippert
Journal:  Chirurg       Date:  2004-02       Impact factor: 0.955

  8 in total
  1 in total

1.  [Differences in chronic back pain and joint disorders among health insurance funds : Results of a cross-sectional study based on the data of the Socioeconomic Panel from 2013].

Authors:  A Luque Ramos; F Hoffmann
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.